Current Situation

Medical Need

As of today, no effective medical device exists for the therapy of Heart Failure with preserved Ejection Fraction.

Heart failure is a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood1. It is a serious condition in which the heart is unable to pump enough blood to meet the needs of the body. The typical symptoms of heart failure are breathlessness, swollen limbs and fatigue. Despite improvements in healthcare over the past 20 years, the outlook for patients with heart failure remains poor and survival rates are worse than those with most cancers2.

Heart failure occurs mainly in two forms Heart Failure with reduced Ejection Fraction (HFrEF) and Heart Failure with preserved Ejection Fraction HFpEF).

Heart Failure with reduced Ejection Fraction (HFrEF), accounting for less than 50% of heart failure patients, is characterized by the thinning of the left ventricular walls, decreased systolic function (Ejection Fraction ≤35-40%) and enlarged left ventricular volume1 3. Heart Failure with preserved Ejection Fraction (HFpEF), accounting for more than 50% of heart failure patients, is characterized by concentric hypertrophy and results in normal sized left ventricular cavity with thickened walls and preserved systolic function (Ejection Fraction >40-50%)1 3.

Socio-Economic Burden

More than 26 million people worldwide are living with heart failure 4,5. Heart failure imposes a huge economic burden, with estimated global overall economic cost of more than $108 billion per annum. Direct costs accounted for ~60% ($65 billion) and indirect costs accounted for ~40% ($43 billion) of the overall spending6. With an aging, rapidly expanding and industrializing global population, this value will continue to rise6.

References

See references here

Solution

The Artract Device

The Artract System is a passive hemodynamic assist device that is implanted percutaneously for the treatment of Heart Failure with preserved Ejection Fraction (HFpEF).

 
 
 

Advantages of the Artract System

Reduces shortness of breath

Artract reduces left atrial blood pressure, easing shortness of breath and improving quality of live.

Improves exercise tolerance

Artract does increase heart chamber filling and stroke volume improving exercise tolerance and live expectancy.

Reduces hospital admission

Efficient treatment of heart failure reduces need for daily medication and frequent hospital stay.

Simplicity

Artract is a fully percutaneously implanted passive device. No energy source or motor is required.

Our Management Team

Powered by People

Tamara McIntosh, MSc

CHIEF EXECUTIVE OFFICER

LEARN MORE

Dipl.-Kfm. Marcus Irsfeld

CHIEF FINANCIAL OFFICER

LEARN MORE

Dr. Wolfgang Götz

CHIEF MEDICAL OFFICER / Chairman (Geschäftsführer)

LEARN MORE

Contact

Get in Touch

Artract Medical GmbH

Am Biopark 13 | 93053 Regensburg | Germany

MEETING US AT EVENTS

We plan to attend the following events and are looking forward to arranging a meeting with you.

 

Currently there are no events.

WIPANO Patentförderung

Förderprogramm WIPANO des Bundesministeriums für Wirtschaft und Energie

External link: http://www.wipano.de

BAFA Invest

Förderprogramm INVEST des Bundesamts für Wirtschaft und Ausfuhrkontrolle

External link: https://www.bafa.de/DE/Wirtschafts_Mittelstandsfoerderung/Beratung_Finanzierung/Invest/invest_node.html